LBA syndicate supports Eagle Genomic’s £1m investment round

Eagle Genomics, a Cambridge based bioinformatics specialist, has closed a £1m investment round from LBA and other investors which included participation from the LBA EIS Roundtable Syndicate Fund 2016. The company is developing software solutions that enable pharmaceutical, biotech and personal care product companies to bring new candidate medicines, therapies and products to patients and customers more quickly. Its range of software solutions, which are already being used by a number of blue chip clients such as Unilever, radically reduce cost and time to complete research which in turn lead to productivity improvements. This new round of funding will enable the company to bolster its marketing and product development activities.

Anthony Clarke, LBA CEO, comments, “Eagle Genomics which is now at scale up stage is commercialising an effective bioinformatics software solution that has the potential to improve the way in which new medicines and therapies are developed. This round of growth capital funding from existing and new angel investors leaves the company well positioned to accelerate its growth in this fast growing market.”